{"nctId":"NCT02256917","briefTitle":"Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A","startDateStruct":{"date":"2015-05","type":"ACTUAL"},"conditions":["Severe Haemophilia A"],"count":58,"armGroups":[{"label":"Human-cl rhFVIII","type":"EXPERIMENTAL","interventionNames":["Biological: Human cl rhFVIII"]}],"interventions":[{"name":"Human cl rhFVIII","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Severe Haemophilia A (FVIII:C \\< 1%)\n* Male patients \\>= 18 years of age\n* Previous treatment with a FVIII concentrate for at least 150 EDs\n* Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start\n* Immunocompetence (CD4+ count \\> 200/uL)\n\nExclusion Criteria:\n\n* Any coagulation disorder other than Haemophilia A\n* Present of past FVIII inhibitor activity\n* Severe liver or kidney disease","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Total Bleeding Rate of Individually Tailored Prophylaxis","description":"Total annualized bleeding rate (ABR) of individually tailored prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"6.46"},{"groupId":"OG001","value":"58.08","spread":"30.78"}]}]}]},{"type":"SECONDARY","title":"Annualized Spontaneous Bleeding Rate of Individually Tailored Prophylaxis","description":"Spontaneous annualized bleeding rate (ABR) of individually tailored prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"5.76"},{"groupId":"OG001","value":"38.46","spread":"28.07"}]}]}]},{"type":"SECONDARY","title":"Annualized Total Bleeding Rate in Patients With 2x/Week (or Less) Prophylaxis","description":"Total annualized bleeding rate (ABR) in patients with 2x/week (or less) prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.82","spread":"6.98"},{"groupId":"OG001","value":"58.08","spread":"30.78"}]}]}]},{"type":"SECONDARY","title":"Median Prophylactic Dosing Interval","description":"Median over median actual dosing intervals between two prophylactic treatments per patient. The median time (hours) between two prophylactic doses of Human-cl rhFVIII in the prophylactic treatment Phase II per patient","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Prophylactic Dosing Interval","description":"Mean over mean actual dosing intervals between two prophylactic treatments per patient. The mean time (hours) between two prophylactic doses of Human-cl rhFVIII in the prophylactic treatment Phase II per patient","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":"22.37"}]}]}]},{"type":"SECONDARY","title":"AUC Divided by the Dose (AUCnorm) of Human-cl rhFVIII","description":"AUCnorm of Human-cl rhFVIII measured using the one-stage (OS) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"0.116"}]}]}]},{"type":"SECONDARY","title":"In-vivo Recovery (IVR) of Human-cl rhFVIII","description":"IVR of Human-cl rhFVIII measured using the one-stage (OS) assay and will be determined from the FVIII level before the infusion and the peak level after the infusion of Human-cl rhFVIII","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.775","spread":"0.421"}]}]}]},{"type":"SECONDARY","title":"Half Life (t1/2) of Human-cl rhFVIII","description":"T1/2 of Human-cl rhFVIII measured using the one-stage (OS) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.725","spread":"4.029"}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time (MRT) of Human-cl rhFVIII","description":"MRT of Human-cl rhFVIII measured using the one-stage (OS) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.762","spread":"5.997"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL) of Human-cl rhFVIII","description":"CL of Human-cl rhFVIII measured using the one-stage (OS) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.859","spread":"1.670"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution at Steady State (Vss) of Human-cl rhFVIII","description":"Vss of Human-cl rhFVIII measured using the one-stage (OS) assay","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.901","spread":"16.454"}]}]}]},{"type":"SECONDARY","title":"Usage of Human-cl rhFVIII (FVIII IU/kg BW Per Week Per Patient)","description":"Average weekly consumption of Human-cl rhFVIII reported as IU/kg BW per week per patient was determined during individualized prophylactic treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":"25.7"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Adverse Events (AEs)","description":"AEs were documented at each (scheduled or unscheduled) study visit. Severity and seriousness of all AEs were documented by the investigator according to pre-defined criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":58},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Pyrexia","Influenza"]}}}